venetoclax
abbvie,roche
['leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'venetoclax']
#ash22 #leusm reville: 2yr efs/os 68%/71%. outcomes look abiut the same in flt3-itd+ (no flt3i given) but small numbers for comparison. really great outcomes in eln favorable risk and were the same for int/high risk. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)